4 completed, 1 recruiting. 5 Phase 3.
By phase and status
Follow B-cell Chronic Lymphocytic Leukemia: new trials by email Literature Review of B-cell Chronic Lymphocytic Leukemia trials Research Report on B-cell Chronic Lymphocytic Leukemia
Trials (filtered) newest first · largest first
All 5 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Xembify, Placebo - Hypogammaglobulinemia, Bacterial Infections | Phase 3 | Recruiting | 386 | 2022-12-26 | 2026-09-30 |
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)
Lenalidomide, Chlorambucil - B-Cell Chronic Lymphocytic Leukemia | Phase 3 | Completed | 450 | 2009-10-13 | 2019-07-09 |
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy
Lenalidomide, Placebo - B-cell Chronic Lymphocytic Leukemia | Phase 3 | Completed | 317 | 2009-01-27 | 2021-12-02 |
Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients
FluCAM [Fludara + Campath], fludarabine phosphate - B-Cell Chronic Lymphocytic Leukemia | Phase 3 | Completed | 335 | 2004-07-01 | 2014-03-13 |
Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients
Fludarabine, Cyclophosphamide, Rituximab - B-Cell Chronic Lymphocytic Leukemia | Phase 3 | Completed | 184 | 2003-12-01 | 2016-11-03 |
Narrower conditions
Leukemia, Lymphocytic, Chronic, B-Cell (5) · Agammaglobulinemia (1) · Bacterial Infections (1) · Lymphoma, Non-Hodgkin (1)
Broader conditions
Chronic Disease (5) · Disease Attributes (5) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Leukemia (5) · Leukemia, B-Cell (5) · Leukemia, Lymphoid (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5)
Interventions
Lenalidomide (2) · Alemtuzumab (1) · Chlorambucil (1) · Cyclophosphamide (1) · Pentostatin (1) · Rituximab (1) · Saline Solution (1) · fludarabine (1) · fludarabine phosphate (1) · gamma-Globulins (1)
Sponsors
Celgene (2) · Genzyme, a Sanofi Company (1) · Grifols Therapeutics LLC (1) · US Oncology Research (1)
Countries
United States (5) · Poland (4) · Romania (4) · Austria (3) · Bulgaria (3) · Canada (3) · Croatia (3) · France (3) · Hungary (3) · Italy (3) · Portugal (3) · Russia (3) · Australia (2) · Belgium (2) · Colombia (2)
Top investigators
Craig Reynolds, MD (1) · Jeffrey Jones, MD (1) · Richard Delarue, MD (1)
Results publications
PMID 21992852, PMID 28140392, PMID 28958469
NIH funding
2004 (1), 2008 (1)